Clinical Trial

Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants

Name: Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants — clinical trial record (NCT07673900)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

VX-201-101 is a first-in-human Phase 1 clinical study evaluating VX-201, a needle-free microneedle (MN) array patch (MAP) that delivers semaglutide through the skin as an alternative to subcutaneous (SC) injection.

Trial Details

NCT Number	NCT07673900
Lead Sponsor	Terrestrial Bio, Inc. Collaborators: Celerion
Conditions	Overweight and/or Obesity
Enrollment	62 participants
Start Date	2026-06-15
Primary Completion	2027-02-10 (estimated)
Study Completion	2027-05-18 (estimated)
Updated on ClinicalTrials.gov	2026-07-31